Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Tamsulosin - 1 week
Tamsulosin- 1 week · 1 trial · 1 indication
The absence of voiding naturally after undergoing thoracic surgery needing an intervention as a Foley catheter or a catheterization. Documentation for first void, Post bladder scan showing more that 300cc of residual urine in the bladder (failure to urinate), or following spontaneous urination if there is more than 300cc of residual urine in the bladder (inadequate urination)
| Arm | Type | Description |
|---|---|---|
| 1 week Pre-operative Tamsulosin administration | EXPERIMENTAL | - |
| 3 days Pre-operative Tamsulosin administration | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Tamsulosin - 1 week | DRUG | The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 1 week), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure. |
| Tamsulosin - 3 days | DRUG | The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 3 days), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure. |
Inclusion Criteria: Males ≥50 years old Planned surgical procedure of a minimally invasive thoracic surgical procedure (wedge resection, segmentectomy, lobectomy, pleural biopsy, or pleurodesis) Surgery scheduled more than 3 days from the time of consent Exclusion Criteria: * Using Flomax alread...
Tamsulosin - 1 week is an investigational small molecule being studied for the treatment of urinary retention, specifically post-operative urinary retention following thoracic surgery. It is currently in Phase 1 clinical development and has not been approved by the FDA.
Tamsulosin - 1 week is being developed by Meridian Bioscience Inc, which trades under the ticker VIVO. The company is conducting a Phase 1 clinical trial to evaluate the drug for urinary retention.
Tamsulosin - 1 week is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by the FDA. The ongoing trial is recruiting participants to study its effects on post-operative urinary retention.
Tamsulosin - 1 week is being studied in a single Phase 1 clinical trial with the identifier NCT03609580. The trial, titled 'Post-operative Urinary Retention (POUR) Following Thoracic Surgery,' is recruiting 127 male participants aged 50 years and older in the United States.
Yes, Tamsulosin - 1 week is also known as Tamsulosin - 1 week. The drug is being developed by Meridian Bioscience Inc for the treatment of urinary retention and is currently in Phase 1 clinical trials.